Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#4659 Current role of systemic lanreotide therapy of patients with advanced, unresectable, non-metastatic paraganglioma / pheochromocytoma (PPGL) sporadic and hereditary

Introduction: Retrospective, performed in prospective manner single-arm, open-label, case series study to assess the efficacy of lanreotide in patients with unresectable, non-metastatic paraganglioma / pheochromocytoma (PPGL) spontaneous or germline mutations.

Conference:

Presenting Author:

Authors: Kolasińska-Ćwikla A, Pęczkowska M, Michałowska I, Pałucki J, Roszkowska-Purska K,

Keywords: Paraganglioma / pheochromocytoma (PPGL) spontaneous or germline mutations, Lanreotide therapy, fractionated metoxycatecholamines,

#4639 Prevalence and characteristics of incidental NET of the Meckel’s diverticula: Retrospective cohort study at a tertiary centre

Introduction: Meckel’s diverticulum is a rare finding in adults but can harbour malignancies such as leiomyosarcoma or neuroendocrine tumours (NET). The clinical presentation and tumour characteristics, including grading, have shown high variability in recent studies for NET.

Conference:

Presenting Author: Berckenhagen L

Authors: Berckenhagen L, Weidemann S, Amin T, Ritter A, Poppinga J,

Keywords: Meckel’s diverticula, incidental NET, acute abdomen, lower GI-bleeding,

#4537 The usefulness of circulating fibrosis markers in detection of carcinoid heart disease

Introduction: Carcinoid heart disease (CHD) is a potential serious fibrotic complication in patients with neuroendocrine neoplasms (NENs), affecting the heart valves. Early detection is crucial to avoid severe manifestations. NT-proBNP is suggested as an initial screening tool in detection of CHD; however, the value of NT-proBNP as a screening tool is questionable.

Conference:

Presenting Author: Lau T

Authors: Lau T, Angeli E, Oksjoki R, Rasmussen V, Genovese F,

Keywords: carcinoid heart disease, biomarker, fibrosis marker,

#4536 Follow-up is not justified in patients with typical lung carcinoids treated with curative intent

Introduction: Typical carcinoids (TC) are well-differentiated neuroendocrine neoplasms of the lung with generally favourable prognosis. Recurrence is rare in TC patients treated with curative intent, yet current ENETS guidelines recommend extensive follow-up, including regular and long-term imaging.

Conference:

Presenting Author: Lau T

Authors: Lau T, Soldath P, Rewitz K, Jepsen P, Knigge U,

Keywords: typical carcinoid, lung nen, follow-up programme,

#4492 Utility of NETest 2.0 as a biomarker for neuroendocrine tumours: The Swiss experience – Real-world data

Introduction: The NETest 2.0 is a PCR assay of circulating mRNA, scored 0-100. It has been developed as a biomarker to diagnose neuroendocrine neoplasia (NEN) and to provide tumour prognostic information.

Conference:

Presenting Author: Chirindel A

Authors: Chirindel A, Wild D, Voegeli M, de Dosso S, Siebenhüner A,

Keywords: NETest, tumour biomarker, NEN, disease presence, disease progression,